Coexistence of Multiple Sclerosis and Ankylosing Spondylitis: Report of Two Cases
| Autor: | D Antoniadis, D. Karacostas, Athanasios Lourbopoulos, E. Boura, Nikolaos Grigoriadis, Panagiotis Ioannidis |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male medicine.medical_specialty Multiple Sclerosis MEDLINE Comorbidity medicine Humans Spondylitis Ankylosing Spondylitis Ankylosing spondylitis medicine.diagnostic_test business.industry Multiple sclerosis Brain Magnetic resonance imaging Middle Aged medicine.disease Spinal cord Magnetic Resonance Imaging Optimal management medicine.anatomical_structure Spinal Cord Neurology Physical therapy Female Neurology (clinical) Radiology business |
| Zdroj: | European Neurology. 70:149-154 |
| ISSN: | 1421-9913 0014-3022 |
| DOI: | 10.1159/000351248 |
| Popis: | Background: Multiple sclerosis (MS) only rarely coexists with ankylosing spondylitis (AS). The optimal management of these patients represents a major challenge. Methods: In the present study, we report 2 cases of AS with definite MS comorbidity. One of the AS-MS cases had received anti-TNFα treatment, which was discontinued due to exacerbation of the MS. In addition, we discuss 3 more AS cases with neurological symptoms and atypical white matter demyelinating MRI lesions after anti-TNFα treatment. Discussion: Given the fact that anti-TNFα drugs can potentially exacerbate a latent MS or induce atypical demyelination in the central nervous system, they should be discouraged or discontinued in relevant cases. The remaining effective therapeutic options for MS are either contradictory for AS (interferon-β), have no definite data regarding their safety/efficacy in AS (glatiramer acetate, azathioprine, natalizumab, fingolimod), or their efficacy in MS-AS is associated with increased treatment risks (rituximab). Any of these proposed treatments may require active patient's informed consent. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|